Interpace Biosciences, Inc. (OTCMKTS:IDXG) Short Interest Update

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a large decline in short interest in May. As of May 29th, there was short interest totaling 10 shares, a decline of 98.8% from the May 14th total of 806 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 17,136 shares, the days-to-cover ratio is currently 0.0 days.

Interpace Biosciences Stock Up 3.6%

Shares of OTCMKTS:IDXG traded up $0.06 during trading on Tuesday, hitting $1.74. 6,642 shares of the stock traded hands, compared to its average volume of 6,259. The company has a market cap of $7.71 million, a price-to-earnings ratio of -34.80 and a beta of 0.59. The company has a fifty day moving average price of $1.92 and a two-hundred day moving average price of $1.62. Interpace Biosciences has a 52-week low of $0.70 and a 52-week high of $2.40.

Interpace Biosciences (OTCMKTS:IDXG) last posted its earnings results on Tuesday, May 12th. The business services provider reported $0.03 earnings per share for the quarter. The firm had revenue of $9.03 million during the quarter. Interpace Biosciences had a net margin of 65.25% and a return on equity of 219.07%.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.